Skip to main content

Table 1 Clinical and molecular characteristics of patients with pediatric acute T-ALL with respect to BRD4 expression

From: BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes

  High BRD4 expression Low BRD4 expression P-Value
Gender, n (%)    0.409
 Male 26 (57) 12 (26)  
 Female 7 (15) 1 (2)  
Age at diagnosis,years,median (range) 7.6 (2.3–11.6) 7.9 (1.2–12.2) 0.232
Hemoglobin, g/L, median (range) 102 (54–152) 105 (49–115) 0.518
Platelet, (× 109/L), median (range) 78 (10–263) 65 (30–206) 0.634
Initial BM blast (%) 87 (24–100) 92 (71–97) 0.191
Initial WBC, (× 109/L), n (%)    1.000
 < 100 14 (31) 5 (11)  
 ≥ 100 19 (4) 8 (17)  
Prednisone Response, n (%)    0.738
 Good 12 (26) 6 (13)  
 Poor 21 (46) 7 (15)  
Day 15th BM, n (%)    0.675
 M1 + M2 20 (43) 7 (15)  
 M3 13 (28) 6 (14)  
D33th BM blast, n (%)    1.000
 M1 29 (63) 11 (24)  
 M2 4 (9) 2 (4)  
Week 12th BM blast, n (%)    0.548
 M1 30 (65) 13 (28)  
 M2 3 (7) 0 (0)  
Risk group, n (%)    0.385
 Intermediate risk 29 (63) 10 (22)  
 High risk 4 (9) 3 (6)  
Relapse, n (%)
 Yes 12 (26) 2 (4) 0.286
 No 21 (46) 11 (24)  
Survival times
 5-years OS, cumulative survival 0.480 ± 0.08 0.846 ± 0.100 0.045
 5-years RFS,cumulative survival 0.577 ± 0.094 0.833 ± 0.108 0.155